📊 REPL Key Takeaways
Is Replimune Group, Inc. (REPL) a Good Investment?
Replimune is a pre-revenue clinical-stage biotech with -$319.9M operating loss and -$280.3M annual cash burn, leaving only ~9 months of runway despite a $209M cash position. The company has zero commercial revenue and is entirely dependent on uncertain clinical trial outcomes, with no clear path to profitability in the near term based on current financial fundamentals.
Replimune remains pre-revenue while operating losses, negative returns, and cash consumption are exceptionally high, with diluted EPS deteriorating year over year. Although near-term liquidity is strong, the current free-cash-flow burn exceeds cash reserves on an annualized basis, creating substantial financing and dilution risk without demonstrated commercial growth.
Replimune Group, Inc. Key Strengths (REPL)
- Strong cash position of $209.0M provides operational runway for planned studies
- Excellent liquidity with 4.79x current ratio indicating ability to meet short-term obligations
- Conservative leverage at 0.50x debt-to-equity ratio with manageable debt service
- Strong current and quick ratios of 4.79x
- Cash and equivalents of $209.02M provide a meaningful liquidity buffer
- Moderate long-term debt relative to equity at 0.50x
REPL Stock Risks: Replimune Group, Inc. Investment Risks
- Zero revenue with no commercial-stage products generating sales
- Unsustainable burn rate of $280.3M annually leaves only ~9 months of cash runway
- Complete financial dependence on uncertain clinical trial outcomes and FDA approval - binary risk
- High likelihood of dilutive capital raise required before reaching profitability or positive cash flow
- Negative ROE (-188.9%) and ROA (-94.4%) reflect severe operational losses
- No revenue or gross profit to support operating expenses
- Free cash flow of negative $284.57M indicates an unsustainable cash-burn rate
- Deeply negative ROE and ROA signal rapid destruction of shareholder capital
Key Metrics to Watch
- Cash runway and burn rate trajectory - critical for assessing capital raise timing
- Clinical trial progress and milestone achievements
- Quarterly cash burn trend - any improvement would extend runway
- Quarterly operating cash burn and remaining cash runway
- Revenue generation and operating-expense trajectory
Replimune Group, Inc. (REPL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.79x current ratio provides a solid financial cushion.
REPL Profit Margin, ROE & Profitability Analysis
REPL vs Healthcare Sector: How Replimune Group, Inc. Compares
How Replimune Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Replimune Group, Inc. Stock Overvalued? REPL Valuation Analysis 2026
Based on fundamental analysis, Replimune Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Replimune Group, Inc. Balance Sheet: REPL Debt, Cash & Liquidity
REPL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Replimune Group, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.07 indicates the company is currently unprofitable.
REPL Revenue Growth, EPS Growth & YoY Performance
REPL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | N/A | -$4.2M | N/A |
| Q2 2018 | N/A | -$4.0M | N/A |
| Q1 2018 | N/A | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Replimune Group, Inc. Dividends, Buybacks & Capital Allocation
REPL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Replimune Group, Inc. (CIK: 0001737953)
📋 Recent SEC Filings
❓ Frequently Asked Questions about REPL
What is the AI rating for REPL?
Replimune Group, Inc. (REPL) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are REPL's key strengths?
Claude: Strong cash position of $209.0M provides operational runway for planned studies. Excellent liquidity with 4.79x current ratio indicating ability to meet short-term obligations. ChatGPT: Strong current and quick ratios of 4.79x. Cash and equivalents of $209.02M provide a meaningful liquidity buffer.
What are the risks of investing in REPL?
Claude: Zero revenue with no commercial-stage products generating sales. Unsustainable burn rate of $280.3M annually leaves only ~9 months of cash runway. ChatGPT: No revenue or gross profit to support operating expenses. Free cash flow of negative $284.57M indicates an unsustainable cash-burn rate.
What is REPL's revenue and growth?
Replimune Group, Inc. reported revenue of $0.0.
Does REPL pay dividends?
Replimune Group, Inc. does not currently pay dividends.
Where can I find REPL SEC filings?
Official SEC filings for Replimune Group, Inc. (CIK: 0001737953) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is REPL's EPS?
Replimune Group, Inc. has a diluted EPS of $-3.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is REPL's fundamental grade?
Based on our AI fundamental analysis in August 2026, Replimune Group, Inc. has a C grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is REPL stock overvalued or undervalued?
Valuation metrics for REPL: ROE of -188.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is REPL's AI grade for 2026?
Our dual AI analysis gives Replimune Group, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is REPL's free cash flow?
Replimune Group, Inc.'s operating cash flow is $-280.3M, with capital expenditures of $4.2M.
How does REPL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -188.9% (avg: 15%), current ratio 4.79 (avg: 2).